Salt Lake City-based Co-Diagnostics Inc. has finished the principle design work for a polymerase chain reaction (PCR) screening test for the novel coronavirus that has sickened nearly 3,000 with an acute respiratory illness and killed more than 80 people in Wuhan, China.
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Avinger, Baylis Medical, Co-Diagnostics, Eptam Precision Solutions, Frazier Healthcare Partners, Fresenius Medical Care, Glaxosmithkline, HG Capital, Intelerad Medical Systems, Investissements Novacap, Myriad Genetics, New Heritage Capital, Oncimmune Holdings, Visquate
LONDON – After a second day of deliberation, the World Health Organization (WHO) held off declaring that the novel coronavirus infection raging in Wuhan is an international health emergency, saying the low number of cases outside China means it is not time to escalate the response to this level.
LONDON – The World Health Organization held off declaring the novel coronavirus infection that has emerged in Wuhan, China, an international public health emergency, despite the fact that the number of confirmed cases tripled in the past week and the infection has spread to several other countries, including the U.S.
In response to the emergence of a new coronavirus seen recently in China, and now America, Novavax Inc. has initiated development of a vaccine candidate, the company told BioWorld. Company shares (NASDAQ:NVAX) climbed more than 71% Jan. 21, ending the day at $9.82.
Researchers at the Christian Albrechts University of Kiel and the MRC London Institute of Medical Science have developed a way to screen four-way interactions between genetically simple hosts, their microbiome, nutrients and drugs.
